DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH
DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH is recorded as a service provider in 24 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 24 trials · Latest update first
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis, followed by an open label extension phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open-label extension phase.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy (OPUS OLE)
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic cardiovascular disease, and elevated LDL-C and Lp(a)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A single-center, randomized, double-blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had insufficient response or relapsed after first line steroid treatment (VAYHIT2)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH?
The 2026-10-09 snapshot links DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH to 24 distinct CTIS trials. Recorded services include Statistical analysis, Independent statistical group for Data Monitoring Committee (DMC), Biostats, DMC, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH?
The most frequently recorded therapeutic areas are Immunology, Neurology, Cardiology, Blood Disorders. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH conducted?
The linked trials record locations in 25 countries, including Spain, Germany, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH delivered services.
What can this page tell me about DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH's trial experience?
Browse 24 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- DATAMAP-Gesellschaft fuer Datenmanagement Datenanalyse und Datenpraesentation mbH